Vitamin D Toxicity: Glucocorticoids or Supportive Care Alone
A single patient whose hypercalcemia has an unusually clear cause once the history is actually taken. The disagreement is over how aggressively to treat a problem that, unlike most causes of severe hypercalcemia, is expected to resolve largely on its own.
Gustaf L., a 58-year-old man, had been taking a vitamin D supplement bought online after reading that higher doses might help with joint pain and general fatigue, self-dosing well above anything his doctors had recommended and, by his own admission, not mentioning it at his last two appointments because he did not think of it as a real medication. Weeks of worsening nausea, constipation and unrelenting thirst finally brought him to urgent care, where a basic metabolic panel found a corrected calcium of 13.8 and prompted transfer. A 25-OH vitamin D drawn once the pattern was clear returned 218 ng/mL.
His presentation is unusual in one clarifying way. Most severe hypercalcemia the team sees traces to malignancy or primary hyperparathyroidism — processes that do not resolve on their own once identified. His does: stopping the supplement removes the source, and his body will eventually clear the excess. His PTH of 8 is what confirms which process is running, appropriately suppressed rather than driving anything, which rules the parathyroid out and rules the exogenous vitamin D in. So the disagreement is not about diagnosis and not about whether he improves. It is about what the word "eventually" is doing in that sentence. Glucocorticoids reduce calcitriol-driven intestinal calcium absorption — the mechanism Davies and colleagues described in their series on glucocorticoid treatment of vitamin-D-mediated hypercalcemia — and that mechanism is specific to this cause in a way it is not for most other hypercalcemias.
The limit on all of this reasoning is that nobody can say how long his particular clearance will take. 25-OH vitamin D has a half-life measured in weeks, and his adipose stores hold an unknown quantity accumulated over months of dosing at a level he never disclosed precisely. Any estimate the team gives him for when this resolves is an extrapolation from a starting point they cannot measure.
How much "self-limited" actually leaves untreated
I'd start prednisone now. It reduces intestinal calcium absorption by suppressing calcitriol-driven transport and can meaningfully accelerate calcium normalization specifically in vitamin D toxicity — the mechanism Davies and colleagues described in their series on glucocorticoid treatment of vitamin-D-mediated hypercalcemia, and one that doesn't apply the same way in most other hypercalcemia causes we manage. His level is high enough to justify actively speeding recovery.
My instinct is supportive care alone — stop the supplement, IV fluids, calcitonin short-term if needed. This is self-limited once the source is removed, and glucocorticoids carry real side effects for a condition that doesn't require them to eventually resolve.
I'm not dismissing the mechanism — I'm questioning whether "eventually resolves" is a good enough answer for how he's feeling right now.
That's really the question worth making concrete. "Self-limited" is true, but it's been doing a lot of work in this conversation without anyone naming how long it actually takes — stored fat-soluble vitamin D can take weeks to clear even after the supplement stops, and his symptoms are real now, not weeks from now.
A defined, time-limited prednisone course, not indefinite therapy, addresses that specific gap — targeted at the actual clearance timeline rather than treated as either mandatory or unnecessary based on the diagnosis category alone.
Agreed: stop the supplement, start IV fluids, and add a short, defined prednisone taper rather than either open-ended steroid therapy or supportive care alone, explicitly to cover the weeks his stored vitamin D is expected to take clearing.
Not fully settled: whether a repeat 25-OH vitamin D level should guide when to stop the prednisone taper, or whether a fixed calendar-based taper is simpler and adequate — the endocrinologist preferred lab-guided tapering, the primary care physician felt a fixed schedule avoided over-monitoring a condition already expected to resolve.